Cited by 211Hemoglobinopathies and Related DisordersBlood groups and transfusionPlatelet Disorders and Treatments

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Open access

Telen, Marilyn J., Wun, Ted, McCavit, Timothy L., De Castro, Laura M., Krishnamurti, Lakshmanan, Lanzkron, Sophie, Hsu, Lewis L., Smith, Wally R., Rhee, Seungshin, Magnani, John L., Thackray, Helen·2015·Blood

DOI 10.1182/blood-2014-06-583351PMC PMC4408290

Open this paper in CoChat — free account Open PDF

Abstract

Key Points: GMI-1070 led to statistically insignificant but large reductions in time to resolution of VOC and a significant reduction in opioid use. These results support a role for selectins in VOC and progression to a phase 3 study of GMI-1070 for SCD patients with vaso-occlusion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2014-06-583351

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422502 · Cited by 1,234
Population Estimates of Sickle Cell Disease in the U.S.
Hassell, K. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.022 · Cited by 1,214
Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates
Piel, F. B., Patil, A. P., Howes, R. E., Nyangiri, O. A., Gething, P. W., Dewi, M., Temperley, W. H., Williams, T. N., Weatherall, D. J., & Hay, S. I. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61229-x · Cited by 1,196
The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain
Kelly, A.-M. (2001) · Emergency Medicine Journal · doi:10.1136/emj.18.3.205 · Cited by 969
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia
Steinberg, M. H., Barton, F. B., Castro, O. L., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E. P., Bellevue, R., Olivieri, N. F., Eckman, J. R., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 928
Self-citation
The inherited diseases of hemoglobin are an emerging global health burden
Weatherall, D. J. (2010) · Blood · doi:10.1182/blood-2010-01-251348 · Cited by 908
Acute Care Utilization and Rehospitalizations for Sickle Cell Disease
Brousseau, D. C. (2010) · JAMA · doi:10.1001/jama.2010.378 · Cited by 636
Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm
Turhan, A., Weiss, L. A., Mohandas, N., Coller, B. S., & Frenette, P. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052522799 · Cited by 487
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
The cost of health care for children and adults with sickle cell disease
Kauf, T. L., Coates, T. D., Liu, H., Mody‐Patel, N., & Hartzema, A. G. (2009) · American Journal of Hematology · doi:10.1002/ajh.21408 · Cited by 388

Show all 34 references

Sorted by citations

Items 101–200 of 211

Targeting Neutrophil Adhesive Events to Address Vaso-Occlusive Crisis in Sickle Cell Patients
Morikis, V. A., Hernandez, A. A., Magnani, J. L., Sperandio, M., & Simon, S. I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663886 · Cited by 21
Self-citation
Glycopeptides and -Mimetics to Detect, Monitor and Inhibit Bacterial and Viral Infections: Recent Advances and Perspectives
Behren, S., & Westerlind, U. (2019) · Molecules · doi:10.3390/molecules24061004 · Cited by 21
Precision Medicine and Sickle Cell Disease
Hoss, S. E., Nemer, W. E., & Rees, D. C. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000762 · Cited by 21
Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in sickle cell disease
Jimenez, M. A., Novelli, E. M., Shaw, G. D., & Sundd, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006742 · Cited by 19
The challenge of clinical end points in sickle cell disease
Ataga, K. I. (2023) · Blood · doi:10.1182/blood.2023021220 · Cited by 19
Perspectives of Carbohydrates in Drug Discovery
Rojo, J., Sousa‐Herves, A., & Mascaraque, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12311-x · Cited by 20
Selectins in Biology and Human Disease: Opportunity in E-selectin Antagonism
Peterson, J. M., Smith, T. A., Rock, E. P., & Magnani, J. L. (2024) · Cureus · doi:10.7759/cureus.61996 · Cited by 18
Self-citation
Selectin-targeting glycosaminoglycan-peptide conjugate limits neutrophil-mediated cardiac reperfusion injury
Dehghani, T., Thai, P. N., Sodhi, H., Ren, L., Sirish, P., Nader, C. E., Timofeyev, V., Overton, J. L., Li, X., Lam, K. S., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa312 · Cited by 18
Advances in new drug therapies for the management of sickle cell disease
Ataga, K. I., & Desai, P. C. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1471983 · Cited by 18
Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
Dhakal, B., Mandhapati, A. R., Eradi, P., Park, S. J., Fibben, K. S., Li, K., DeYong, A. E., Escopy, S., Karki, G., Park, D., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05090 · Cited by 17
Glycan Therapeutics: Resurrecting an Almost Pharma‐Forgotten Drug Class
Paderi, J. E., Prestwich, G. D., Panitch, A., Boone, T., & Stuart, K. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800082 · Cited by 20
Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?
Mattè, A., Cappellini, M. D., Iolascon, A., Federti, E., & Franceschi, L. D. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1703947 · Cited by 17
Sickle cell disease in the new era: advances in drug treatment
Lee, M. T., & Ogu, U. O. (2022) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2022.103555 · Cited by 15
Base-modified UDP-sugars reduce cell surface levels of P-selectin glycoprotein 1 (PSGL-1) on IL-1β-stimulated human monocytes
Kanabar, V., Tedaldi, L. M., Jiang, J., Nie, X., Panina, I. S., Descroix, K., Man, F., Pitchford, S. C., Page, C. P., & Wagner, G. K. (2016) · Glycobiology · doi:10.1093/glycob/cww053 · Cited by 15
Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling
Morrone, K. A., Mitchell, W. B., & Manwani, D. G. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.007 · Cited by 15
Small molecule therapeutics to treat the β-globinopathies
Yu, L., Myers, G., & Engel, J. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000579 · Cited by 15
An update review of new therapies in sickle cell disease: the prospects for drug combinations
Lugthart, S., Ginete, C., Kuona, P., Brito, M., & Inusa, B. P. D. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2317336 · Cited by 14
A Peptide Analogue of Selectin Ligands Attenuated Atherosclerosis by Inhibiting Monocyte Activation
Ye, Z., Zhang, S., Liu, Y., Wang, S., Zhang, J., & Huang, R. (2019) · Mediators of Inflammation · doi:10.1155/2019/8709583 · Cited by 14
Retracted
Prasugrel hydrochloride for the treatment of sickle cell disease
Conran, N., & Rees, D. C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1335710 · Cited by 14
Covalent Lectin Inhibition and Application in Bacterial Biofilm Imaging
Wagner, S., Hauck, D., Hoffmann, M., Sommer, R., Joachim, I., Müller, R., Imberty, A., Varrot, A., & Titz, A. (2017) · Angewandte Chemie · doi:10.1002/ange.201709368 · Cited by 14
Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease
Bhatt, S., Argueta, D. A., Gupta, K., & Kundu, S. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0348 · Cited by 13
Sickle Cell Disease
Kunz, J. B., & Tagliaferri, L. (2024) · Transfusion Medicine and Hemotherapy · doi:10.1159/000540149 · Cited by 14
A Growing Population of Older Adults with Sickle Cell Disease
Shet, A. S., & Thein, S. L. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.03.006 · Cited by 15
Clinical Manifestations of Sickle Cell Disease Across the Lifespan
Pecker, L. H., & Little, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62328-3_1 · Cited by 14
Optimal disease management and health monitoring in adults with sickle cell disease
Howard, J., & Thein, S. L. (2019) · Hematology · doi:10.1182/hematology.2019000055 · Cited by 14
Going Native: Synthesis of Glycoproteins and Glycopeptides via Native Linkages To Study Glycan-Specific Roles in the Immune System
Marqvorsen, M. H. S., Araman, C., & van Kasteren, S. I. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00588 · Cited by 12
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease
Rossato, P., Glantschnig, H., Canneva, F., Schuster, M., Coulibaly, S., Schrenk, G., Voelkel, D., Dockal, M., Plaimauer, B., Rottensteiner, H., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.10.016 · Cited by 11
The emerging role for red blood cells in haemostasis: opportunity for intervention
Villa, C. H., Muzykantov, V. R., & Cines, D. B. (2016) · ISBT Science Series · doi:10.1111/voxs.12197 · Cited by 11
Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease
Gu, J.-M., Yuan, S., Sim, D., Abe, K. Y., Liu, P., Rosenbruch, M., Bringmann, P., & Kauser, K. Z. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.01.002 · Cited by 11
Characterization and statistical modeling of glycosylation changes in sickle cell disease
Ashwood, H. E., Ashwood, C., Schmidt, A. P., Gundry, R. L., Hoffmeister, K. M., & Anani, W. Q. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003376 · Cited by 11
The Evolving Landscape of Drug Therapies for Sickle Cell Disease
Rai, P., Desai, P. C., & Ataga, K. I. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.06.008 · Cited by 12
Using disease-modifying therapies in sickle cell disease
Rai, P., & Ataga, K. I. (2023) · Hematology · doi:10.1182/hematology.2023000485 · Cited by 10
Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode
Bakshi, N., Lukombo, I., Belfer, I., & Krishnamurti, L. (2018) · Journal of Pain Research · doi:10.2147/jpr.s150066 · Cited by 10
Self-citation
MEK1/2 as a Therapeutic Target in Sickle Cell Disease
Zennadi, R. (2019) · International Journal of Blood Research and Disorders · doi:10.23937/2469-5696/1410038 · Cited by 10
Smooth Muscle Cells: A Novel Site of P-Selectin Expression with Pathophysiological and Therapeutic Relevance in Pulmonary Hypertension
Sundd, P., & Kuebler, W. M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201812-2242ed · Cited by 10
Biomarkers and recent advances in the management and therapy of sickle cell disease
Telen, M. J. (2015) · F1000Research · doi:10.12688/f1000research.6615.1 · Cited by 9
Self-citation
Age-dependent characterization of carotid and cerebral artery geometries in a transgenic mouse model of sickle cell anemia using ultrasound and microcomputed tomography
Rivera, C. P., Li, L., Cai, S., Pei, N., McAlear, G. E., Bollavaram, K., Ariyo, O. V., Omojola, V. O., Song, H. W., Alfonso, A. L., et al. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102486 · Cited by 9
Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project
Smith, W. R., McClish, D. K., Levenson, J. L., Aisiku, I. P., Dahman, B. A., Bovbjerg, V. E., Roseff, S. D., & Roberts, J. D. (2017) · Pain Medicine · doi:10.1093/pm/pnx214 · Cited by 9
Self-citation
Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease
Lindner, J. R., Belcik, T. A., Widlansky, M. E., Harmann, L. M., Karafin, M. S., Wandersee, N. J., Puligandla, M., Neuberg, D. S., Linden, J. M., & Field, J. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218783 · Cited by 9
Therapeutic Strategies for the Treatment of Sickle Cell Disease
Safo, M. K., Aljahdali, A. S., Burnett, J. C., Abraham, D. J., & Abdulmalik, O. Y. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc270 · Cited by 9
Developing new pharmacotherapeutic approaches to treating sickle‐cell disease
Telen, M. J. (2016) · ISBT Science Series · doi:10.1111/voxs.12305 · Cited by 8
Self-citation
Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease
Li, J., Jeong, S., Xiong, B., Tseng, A., Mahon, A. B., Isaacman, S., Gordeuk, V. R., & Cho, J. (2019) · Haematologica · doi:10.3324/haematol.2019.226720 · Cited by 8
Plasma levels of E‐selectin are associated with retinopathy in sickle cell disease
Agouti, I., Masson, E., Loundou, A., Jean, E., Arnaud, L., Abdili, E., BERENGER, P., Lavoipierre, V., Seguier, J., Dignat‐George, F., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13902 · Cited by 7
Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?
Field, J. J. (2015) · Hematology · doi:10.1182/asheducation-2015.1.426 · Cited by 7
New and emerging treatments for vaso-occlusive pain in sickle cell disease
Dampier, C. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1649131 · Cited by 7
Opportunities for the treatment of atherosclerosis: Selectins
Li, N., Pi, C., Zhu, S., Li, X., Wang, L., Shi, P., Zuo, Y., Zheng, W., Jiang, J., Yang, Y., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107807 · Cited by 7
Sickle Cell Disease
Saunthararajah, Y., & Vichinsky, E. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00042-1 · Cited by 6
The Role of Platelets in Sickle Cell Disease
Brzóska, T., Kato, G. J., & Sundd, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00031-x · Cited by 6
Dose Selection Based on Modeling and Simulation for Rivipansel in Pediatric Patients Aged 6 to 11 Years With Sickle Cell Disease
Tammara, B. K., & Harnisch, L. O. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12263 · Cited by 6
Realizing the promise of ‘La Dolce Vita’ via chemical biology: glycan‐motif editing of sLeX for precision cancer therapeutics
Richichi, B., & Sackstein, R. (2025) · FEBS Journal · doi:10.1111/febs.70079 · Cited by 5
Ser/Thr protein kinase Bβ-NADPH oxidase 2 signaling in thromboinflammation
Li, J., & Cho, J. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000365 · Cited by 5
Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials
Mercier‐Ross, J., Forté, S., & Soulières, D. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2105835 · Cited by 5
Can Crude Oil Exploration Influence the Phytochemicals and Bioactivity of Medicinal Plants? A Case of Nigerian Vernonia amygdalina and Ocimum gratissimum
Diyaolu, O. A., Oluwabusola, E. T., Attah, A. F., Olori, E. O., Fagbemi, A. A., Preet, G., Soldatou, S., Moody, J. O., Jaspars, M., & Ebel, R. (2022) · Molecules · doi:10.3390/molecules27238372 · Cited by 5
Orphan drugs for sickle vaso-occlusion: dawn of a new era of targeted treatment
Dampier, C. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s46305 · Cited by 5
Prodrugs of E‐selectin Antagonists with Enhanced Pharmacokinetic Properties
Dätwyler, P., Jiang, X., Wagner, B., Varga, N., Mühlethaler, T., Hostettler, K., Rabbani, S., Schwardt, O., & Ernst, B. (2021) · ChemMedChem · doi:10.1002/cmdc.202100634 · Cited by 5
Opportunities for model-based precision dosing in the treatment of sickle cell anemia
Dong, M., Mizuno, T., & Vinks, A. A. T. M. M. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.007 · Cited by 5
A Scientific Renaissance
Zaidi, A. U., & Heeney, M. M. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.006 · Cited by 5
Innovations in Targeted Anti‐Adhesion Treatment for Sickle Cell Disease
Kanter, J., & Lanzkron, S. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1682 · Cited by 5
Self-citation
Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease
Brittain, J. E., Anea, C. B., Desai, P. C., Delaney, J., McDonald, A., Looney, S. W., Key, N. S., Parise, L. V., & Ataga, K. I. (2018) · American Journal of Hematology · doi:10.1002/ajh.25032 · Cited by 5
Disrupted homeostasis in sickle cells: Expanding the comprehension of metabolism adaptation and related therapeutic strategies
Bernardo, V. S., Torres, F. F., Zucão, A. C. A., Chaves, N. A., Santana, I. L. R., & da Silva, D. G. H. (2025) · Tissue and Cell · doi:10.1016/j.tice.2024.102717 · Cited by 4
From Native Glycosaminoglycans to Mimetics: Design, Mechanisms, and Biomedical Applications
Junker, F., & Rother, S. (2025) · Biomolecules · doi:10.3390/biom15111518 · Cited by 4
Emerging functional microfluidic assays for the study of thromboinflammation in sickle cell disease
An, R., & Gurkan, U. A. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000731 · Cited by 4
The Benefits and Challenges of Preconsent in a Multisite, Pediatric Sickle Cell Intervention Trial
Nimmer, M., Czachor, J. D., Turner, L. B., Thomas, B., Woodford, A. L., Carpenter, K., Gonzalez, V., Liem, R. I., Ellison, A. M., Casper, T. C., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26013 · Cited by 4
Lack of Effect of Rivipansel on QTc Interval in Healthy Adult African American Male Subjects
Tammara, B. K., Plotka, A., Shafer, F. E., Readett, D., Riley, S., & Korth-Bradley, J. M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.924 · Cited by 5
Evaluation of a Non-Parenteral Opioid Analgesia Protocol for Acute Sickle Cell Pain Episodes in Children
Telfer, P. T., Barroso, F., Newell, K., Challands, J., & Kaya, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101728 · Cited by 4
Preliminary validity of a daily functional status pain assessment tool
Smith, W. R., Qayyum, R., Ulbing, A., Guy, M., Sop, D. M., & Zhang, Y. M. (2025) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoaf006 · Cited by 3
Self-citation
Can red blood cell function assays assess response to red cell-modifying therapies?
White, J., Lancelot, M., Gao, X., Tarasev, M., Chakraborty, S., Emanuele, M., & Hines, P. C. (2021) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-200944 · Cited by 3
Stroke in sickle cell patients, epidemiology, pathophysiology, systemic and surgical treatment options and prevention strategies
Shah, S., Alberts, A. H., Ngo, T. B., & Lucke-Wold, B. P. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.303 · Cited by 3
Pathobiology of Sickle Cell Disease Vaso-occlusion and Targeted Therapies
Morrone, K. A., Davila, J. G., Mitchell, W. B., & Manwani, D. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-62328-3_2 · Cited by 3
Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel
Tammara, B. K., Ryan, K., Plotka, A., Shafer, F. E., Wei, H., Readett, D., Fang, A. F., & Korth-Bradley, J. M. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.842 · Cited by 3
Black Americans’ willingness to participate in pediatric sickle cell clinical trials: A retrospective, systematic review
Zanfardino, S., Mazziotto, V., & Bodas, P. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29580 · Cited by 3
Interactions of sickle red blood cells with neutrophils are stabilized on endothelial cell layers
Dominical, V. M., Vital, D. M., Garrido, V. T., Silveira, A. A. A., Saad, S. T. O., Costa, F. F., & Conran, N. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.10.006 · Cited by 3
Leukocytes in the Vaso-Occlusive Process
Zhang, D., & Frenette, P. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-06713-1_5 · Cited by 3
Hemolysis and innate immunity contribution to sickle cell disease pathophysiology
Maciel, T. T., Rignault‐Bricard, R., Allali, S., & Hermine, O. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005751 · Cited by 2
Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases
Zhong, X., D’Antona, A. M., & Rouse, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211962 · Cited by 2
Exploring the Inhibitory Effects of Fucosylated Chondroitin Sulfate (FCS) Oligosaccharide Isolated from Stichopus horrens and the Derivatives on P-Selectin
Li, C., Sun, H., Gu, X. S., Long, W., Zhu, G., Wu, X., Wang, Y., Li, P., Sha, L., Zhang, J., et al. (2025) · Marine Drugs · doi:10.3390/md23060236 · Cited by 2
Recent advances in the development of promising carbohydrate-based therapeutics
Aslam, N. A., Kyriukha, Y. A., & Janetka, J. W. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2547890 · Cited by 2
Une nouvelle ère thérapeutique dans la drépanocytose
Arlet, J. B. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.05.006 · Cited by 2
Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease
Nayak, S., Tammara, B. K., & Harnisch, L. O. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00346-3 · Cited by 2
A non-injected opioid analgesia protocol for acute pain crisis in adolescents and adults with sickle cell disease
Telfer, P. T., Bestwick, J. P., Elander, J., Osias, A., Khalid, N., Skene, I., Nzouakou, R., Challands, J., Barroso, F., & Kaya, B. (2021) · British Journal of Pain · doi:10.1177/20494637211033814 · Cited by 2
Current Non-HSCT Treatments for SCD
Anderson, C. L., & Darbari, D. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-62328-3_3 · Cited by 2
Avancées thérapeutiques dans la drépanocytose : vers des thérapies ciblées
Arlet, J. B. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.11.001 · Cited by 2
Downregulation of P-Selectin Glycoprotein Ligand-1 as a Potential Anti-Inflammatory Mechanism
Wagner, G. K. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0119 · Cited by 2
Revisiting the structural basis for biological activity of GMI-1070, a sialyl Lewisx mimetic
Arend, L. B., & Verli, H. (2023) · Carbohydrate Research · doi:10.1016/j.carres.2023.108829 · Cited by 1
Inherited Blood Disorders: Advances in Diagnosis and Treatment of Sickle Cell Disease
Shrestha, A. N., & Gyawali, S. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010671 · Cited by 1
Emergency care for children with sickle cell disease: a focus on pain and fever
Korman, R., Hatabah, D., & Morris, C. R. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2538537 · Cited by 1
Can Preconsent Eliminate Some Barriers to Clinical Trial Enrollment of Children With Sickle Cell Disease in Crisis?
Guilcher, G. M. T. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26057 · Cited by 1
Determination of Glycolipid Ligands of Carbohydrate-Binding Proteins Directly on Thin Layer Chromatograms
Magnani, J. L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8552-4_21 · Cited by 1
Self-citation
Gentherapie von Hämoglobinkrankheiten – aktuelle Konzepte und Herausforderungen
Kulozik, A. E., & Kunz, J. B. (2019) · Transfusionsmedizin · doi:10.1055/a-0825-9666 · Cited by 2
Ups and downs in the treatment of sickle cell disease
Brousse, V. A. M. (2023) · Blood · doi:10.1182/blood.2022018075 · Cited by 1
Interactions between leukocytes, platelets and the endothelium in vein graft failure
Tseng, C. (2015) · Figshare
The Role of STAT3 in the Pathogenesis of Chronic Lymphocytic Leukaemia
Brophy, S. (2018) · Trinity's Access to Research Output (TARA) (Trinity College Dublin)
Regulation of Sickle Cell Disease Specific Erythrocyte Adhesion
Zhang, J. (2019) · OpenCommons at University of Connecticut (University of Connecticut)
Was ist neu in der Diagnostik und Therapie der Hämoglobinopathien?
Cario, H., & Lobitz, S. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0601-4921
New Therapeutic Frontiers in Sickle Cell Disease
Quinn, C. T. (2016) · The Hematologist · doi:10.1182/hem.v13.1.4827
Diagnostic and prognostic capacity of serum glycan nodes in different types of cancer
Roshdiferdosi, S. (2018)
Caractérisation fonctionnelle de la réaction biotine synthase de Arabidopsis thaliana: l'importance de la mitochondrie végétale dans la synthèse de la biotine
Picciocchi, A. (2003) · OpenGrey (Institut de l'Information Scientifique et Technique)
Hemostatic Aspects of Sickle Cell Disease
Ataga, K. I., & Lottenberg, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00041-8
Glycomimetics
Kawashima, H., Tsubata, T., Arata, Y., Inokuchi, J., Kizuka, Y., & Manabe, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-5856-2_9
Targeting P-selectin ligands: ushering in a new treatment paradigm for Sickle Cell Disease
Saad, A. A. (2021) · Hematology & Transfusion International Journal · doi:10.15406/htij.2021.09.00270

Authors: Telen, M. J., Wun, T., McCavit, T. L., De Castro, L. M., Krishnamurti, L., Lanzkron, S., Hsu, L. L., Smith, W. R., Rhee, S., Magnani, J. L., & Thackray, H.
Affiliations: Duke University (US)
VA Northern California Health Care System (US)
The University of Texas Southwestern Medical Center (US)
Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA;
Emory University (US)
Johns Hopkins University (US)
University of Illinois Chicago (US)
Virginia Commonwealth University (US)
Rho (United States) (US)
GlycoMimetics (United States) (US)
ORCID: Telen, Marilyn J.
Wun, Ted
Krishnamurti, Lakshmanan
Lanzkron, Sophie
Hsu, Lewis L.
Smith, Wally R.
Venue: Blood
Publisher: American Society of Hematology
Published: 2015-04-23
Volume: 125
Issue: 17
Pages: 2656-2664
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2014-06-583351
PMC: PMC4408290
OpenAlex: W2077716817
Cited by: 211
References: 34
Citations by year: 2026: 2 · 2025: 11 · 2024: 10 · 2023: 8 · 2022: 10 · 2021: 20 · 2020: 24 · 2019: 36 · 2018: 27 · 2017: 24 · 2016: 24 · 2015: 13
FWCI: 16.41
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: University of California
Children's Hospital of Philadelphia
University of Miami
Emory University
Cincinnati Children's Hospital Medical Center
Harvard University
Johns Hopkins University
University of Cincinnati
Virginia Commonwealth University
Children's National Hospital
Hospital for Sick Children
University of Illinois at Urbana-Champaign
Leonard M. Miller School of Medicine
University of Colorado Denver
Children's Hospital of Pittsburgh
Topics: Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Health Sciences › Medicine › Hematology › Blood groups and transfusion
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: sickle cell disease, vaso-occlusive crisis, selectin inhibitors, cell adhesion, opioid analgesic use, time to resolution, drug safety
MeSH terms: Adolescent, Adult, Analgesics, Analgesics, Opioid, Anemia, Sickle Cell, Child, Double-Blind Method, Female, Glycolipids, Humans, Male, Middle Aged, Prospective Studies, Vascular Diseases, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks